KY1005 binds to OX40-Ligand and has the potential to treat a wide variety of immune-mediated diseases and inflammatory disorders.... Jan 13
Sanofi and Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapeutics... Jan 11
The broad-spectrum antiviral therapeutic, 'hzVSF-v13(humanized Virus Suppressing Factor)' being developed by ImmuneMed, is on track to progress as a treatment for the ... Dec 21
R&D collaboration building on Lead Pharma's expertise in the discovery, design and optimization of small molecule treatments ... Nov 16
-Advertisements-